Perou CM, Sørile T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature 2000;406:747-52. DOI: https://doi.org/10.1038/35021093

Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 2001;98:10869-74. DOI: https://doi.org/10.1073/pnas.191367098

Prat A, Adamo B, Cheang MCU, et al. Molecular characterization of basal like and non basal like triple negative breast cancer. Oncologist 2013;18:123-33. DOI: https://doi.org/10.1634/theoncologist.2012-0397

Wang DY, Jiang Z, Ben-David Y, et al. Molecular stratification within triple-negative breast cancer subtypes. Sci Rep 2019;9:1-10. DOI: https://doi.org/10.1038/s41598-019-55710-w

Chang-Qing Y, Jie L, Shi-Qi Z, et al. Recent treatment progress of triple negative breast cancer. Prog Biophys Mol Biol 2020;151:40-53. DOI: https://doi.org/10.1016/j.pbiomolbio.2019.11.007

Polónia A, Pinto R, Cameselle-Teijeiro JF, et al. Prognostic value of stromal tumor infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer. J Clin Pathol 2017;70:860-7. DOI: https://doi.org/10.1136/jclinpath-2016-203990

Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121:1-17. DOI: https://doi.org/10.1172/JCI45014

Majumder A, Jagani R, Basu A. Double-positive in triple-negative? how significant is basal cytokeratin expression in breast cancer? Med J Armed Forces India 2020;76:63-70. DOI: https://doi.org/10.1016/j.mjafi.2018.10.002

Teixeira L, Rothé F, Ignatiadis M, Sotiriou C. Breast cancer immunology. Oncol Times 2016;38:18-9. DOI: https://doi.org/10.1097/01.COT.0000483221.52404.e3

Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumor-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 2018;19:40-50. DOI: https://doi.org/10.1016/S1470-2045(17)30904-X

Keenan TE, Tolaney SM. Role of immunotherapy in triple-negative breast cancer. J Natl Compr Cancer Netw 2020;18:479-89. DOI: https://doi.org/10.6004/jnccn.2020.7554

Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8. DOI: https://doi.org/10.1038/ni1102-991

Gibson J. Anti-PD-L1 for metastatic triple-negative breast cancer. Lancet Oncol 2015;16:e264. DOI: https://doi.org/10.1016/S1470-2045(15)70208-1

Butte MJ, Keir ME, Phamduy TB, et al. Programmed death-1 ligand 1 interacts specifically with the b7-1 costimulatory molecule to inhibit t cell responses. Immunity 2007;27:111-22. DOI: https://doi.org/10.1016/j.immuni.2007.05.016

Matikas A, Zerdes I, Lövrot J, et al. Prognostic implications of PD-L1 expression in breast cancer: systematic review and meta-analysis of immunohistochemistry and pooled analysis of transcriptomic data. Clin Cancer Res 2019;25:5717-26. DOI: https://doi.org/10.1158/1078-0432.CCR-19-1131

Guo Y, Yu P, Liu Z, et al. Prognostic and clinicopathological value of programmed death ligand-1 in breast cancer: A meta-analysis. PLoS One 2016;11:1-11. DOI: https://doi.org/10.1371/journal.pone.0156323

Li X, Li M, Lian Z, et al. Prognostic role of programmed death ligand-1 expression in breast cancer: a systematic review and meta-analysis. Target Oncol 2016;11:753-61. DOI: https://doi.org/10.1007/s11523-016-0451-8

Kim HM, Lee J, Koo JS. Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: A meta-analysis. BMC Cancer 2017;17:1-11. DOI: https://doi.org/10.1186/s12885-017-3670-1

Wang C, Zhu H, Zhou Y, et al. Prognostic value of PD-L1 in breast cancer: a meta-analysis. Breast J 2017;23:436-43. DOI: https://doi.org/10.1111/tbj.12753

Zhang M, Sun H, Zhao S, et al. Expression of PD-L1 and prognosis in breast cancer: A meta-analysis. Oncotarget 2017;8:31347-54. DOI: https://doi.org/10.18632/oncotarget.15532

Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: The prisma statement. PLoS Med 2009;6:1-6. DOI: https://doi.org/10.1371/journal.pmed.1000097

Wells G, Shea B, O’Connell D, et al. The newcastle-ottawa scale (nos) for assessing the quality of nonrandomised studies in meta-analysis. The Ottawa Hospital Research Intitute 2014.

Benford D, Halldorsson T, Jeger MJ, et al. The principles and methods behind EFSA’s guidance on uncertainty analysis in scientific assessment. EFSA J 2018;16:1-234. DOI: https://doi.org/10.2903/j.efsa.2018.5122

Jawhar NMT. Tissue microarray: a rapidly evolving diagnostic and research tool. Ann Saudi Med 2009;29:123-7. DOI: https://doi.org/10.4103/0256-4947.51806

Beckers RK, Selinger CI, Vilain R, et al. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and improved outcome. Histopathology 2016;69:25-34. DOI: https://doi.org/10.1111/his.12904

Bae SB, Cho HD, Oh MH, et al. Expression of programmed death receptor ligand 1 with high tumor-infiltrating lymphocytes is associated with better prognosis in breast cancer. J Breast Cancer 2016;19:242-51. DOI: https://doi.org/10.4048/jbc.2016.19.3.242

Guo L, Li W, Zhu X, et al. PD-L1 expression and cd274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker. Springerplus 2016;5:1-8. DOI: https://doi.org/10.1186/s40064-016-2513-x

Wang ZQ, Milne K, Derocher H, et al. PD-L1 and intratumoral immune response in breast cancer. Oncotarget 2017;8:51641-51. DOI: https://doi.org/10.18632/oncotarget.18305

Ren X, Wu H, Lu J, et al. Pd1 protein expression in tumor infiltrated lymphocytes rather than PD-L1 in tumor cells predicts survival in triple-negative breast cancer. Cancer Biol Ther 2018;19:373-80. DOI: https://doi.org/10.1080/15384047.2018.1423919

Ali HR, Glont SE, Blows FM, et al. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumors and associated with infiltrating lymphocytes. Ann Oncol 2015;26:1488-93. DOI: https://doi.org/10.1093/annonc/mdv192

Sabatier R, Finetti P, Mamessier E, et al. Prognostic and predictive value of PD-L1 expression in breast cancer. Oncotarget 2015;6:5449-64. DOI: https://doi.org/10.18632/oncotarget.3216

Stovgaard ES, Dyhl-Polk A, Roslind A, et al. PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review. Breast Cancer Res Treat 2019;174:571-84. DOI: https://doi.org/10.1007/s10549-019-05130-1

Dogra A, Mehta A, Doval DC. Are basal-like and non-basal-like triple-negative breast cancers really different? J Oncol 2020;2020:1-9. DOI: https://doi.org/10.1155/2020/4061063

Karnik T, Kimler BF, Fan F, et al. PD-L1 in breast cancer: comparative analysis of 3 different antibodies. Hum Pathol 2018;72:28-34. DOI: https://doi.org/10.1016/j.humpath.2017.08.010

Qin T, Zeng YD, Qin G, et al. High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. Oncotarget 2015;6:33972-81. DOI: https://doi.org/10.18632/oncotarget.5583

Food and Drug Administration. Fda grants accelerated approval to pembrolizumab for locally recurrent unresectable or metastatic triple negative breast cancer; 2020.

Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (keynote-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. J Clin Oncol 2020;396:1817-28.

Wang X, Teng F, Kong L, et al. PD-L1 expression in human cancers and its association with clinical outcomes. OncoTargets Ther 2016;9:5023-39. DOI: https://doi.org/10.2147/OTT.S105862

Schalper KA, Velcheti V, Carvajal D, et al. In situ tumor PD-L1 mrna expression is associated with increased TIand better outcome in breast carcinomas. Clin Cancer Res 2014;20:2773-82. DOI: https://doi.org/10.1158/1078-0432.CCR-13-2702